(Reuters) -British consumer healthcare group Haleon’s first-quarter organic revenue growth beat expectations on Wednesday as strong growth in oral health products offset weakness in respiratory health and digestive health products.
Organic revenue for the three months ending March 31 grew 3.5%, and analysts were expecting a growth of 3.2%, according to a company-compiled consensus.
Growing demand for Haleon’s oral hygiene products, which includes Sensodyne and Parodontax, helped cushion the impact of lower revenue from its respiratory health and digestive health portfolio that include products like Otrivin and ENO.
Haleon reaffirmed its 2025 guidance and said it continues to expect the macroeconomic environment to remain “challenging and uncertain”.
(Reporting by Chandini Monnappa and Raechel Thankam Job in Bengaluru; Editing by Mrigank Dhaniwala)
